Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma

Abstract

Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsufficiency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to define the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6+/−) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsufficiency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin-dependent kinase inhibitor p21.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Abbreviations

KLF6:

Kruppel-like factor 6

wtKLF6:

wild-type KLF6

qRT–PCR:

quantitative real-time PCR

WT:

wild type

TG:

transgenic

References

  • Alberici P, Jagmohan-Changur S, De Pater E, Van Der Valk M, Smits R, Hohenstein P et al. (2006). Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene 25: 1841–1851.

    Article  CAS  Google Scholar 

  • Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS et al. (2004). Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 64: 3885–3891.

    Article  CAS  Google Scholar 

  • Bieker JJ . (2001). Kruppel-like factors: three fingers in many pies. J Biol Chem 276: 34355–34358.

    Article  CAS  Google Scholar 

  • Bissell DM, Guzelian PS . (1980). Phenotypic stability of adult rat hepatocytes in primary monolayer culture. Ann N Y Acad Sci 349: 85–98.

    Article  CAS  Google Scholar 

  • Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M et al. (2002). Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between sp1 and KLF6: their potential role in the response to vascular injury. Blood 100: 4001–4010.

    Article  CAS  Google Scholar 

  • Boyault S, Herault A, Balabaud C, Zucman-Rossi J . (2005). Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology 41: 681–682 author reply 682–683.

    Article  Google Scholar 

  • Chen C, Hyytinen E R, Sun X, Helin HJ, Koivisto PA, Frierson HF et al. (2003). Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 162: 1349–1354.

    Article  CAS  Google Scholar 

  • Chen HK, Liu XQ, Lin J, Chen TY, Feng QS, Zeng YX . (2002). Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 21: 1047–1050.

    PubMed  Google Scholar 

  • Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW et al. (2005). Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24: 4588–4590.

    Article  CAS  Google Scholar 

  • Difeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE et al. (2006). E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 25: 6026–6031.

    Article  CAS  Google Scholar 

  • DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL et al. (2006). Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 12: 3730–3739.

    Article  CAS  Google Scholar 

  • el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993). Waf1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.

    Article  CAS  Google Scholar 

  • Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RH, Gerald WL . (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113: 913–923.

    Article  CAS  Google Scholar 

  • Ito G, Uchiyama M., Kondo M, Mori S, Usami N, Maeda O et al. (2004). Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 64: 3838–3843.

    Article  CAS  Google Scholar 

  • Jeng YM, Hsu HC . (2003). KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 105: 625–629.

    Article  CAS  Google Scholar 

  • Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I et al. (2004). Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 149: 98–106.

    Article  CAS  Google Scholar 

  • Kim Y, Ratziu V, Choi SG, Lalazar A, Theiss G, Dang Q et al. (1998). Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. J Biol Chem 273: 33750–33758.

    Article  CAS  Google Scholar 

  • Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD et al. (2004). Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 23: 5077–5083.

    Article  CAS  Google Scholar 

  • Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S et al. (2006). Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol Nov 27 [Epub ahead of print].

  • Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A et al. (2004). Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40: 1047–1052.

    Article  CAS  Google Scholar 

  • Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N et al. (2001). Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98: 11563–11568.

    Article  CAS  Google Scholar 

  • Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al. (2004). Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.

    Article  CAS  Google Scholar 

  • Matsumoto N, Kubo A, Liu H, Akita K, Laub F, Ramirez F et al. (2006). Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood 107: 1357–1365.

    Article  CAS  Google Scholar 

  • Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E et al. (2005). A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65: 1213–1222.

    Article  CAS  Google Scholar 

  • Narla G, Friedman SL, Martignetti JA . (2003). Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 162: 1047–1052.

    Article  Google Scholar 

  • Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC et al. (2001). KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294: 2563–2566.

    Article  CAS  Google Scholar 

  • Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY . (2006). Inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B 7: 830–836.

    Article  CAS  Google Scholar 

  • Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S et al. (2004). Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126: 1090–1103.

    Article  CAS  Google Scholar 

  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203–209.

    Article  CAS  Google Scholar 

  • Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL . (2004). A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene 23: 8196–8205.

    Article  CAS  Google Scholar 

  • Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH et al. (2006). Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1286–1289.

    Article  CAS  Google Scholar 

  • Venkatachalam S, Tyner SD, Pickering CR, Boley S, Recio L, French JE et al. (2001). Is p53 haploinsufficient for tumor suppression? Implications for the p53+/− mouse model in carcinogenity testing. Toxicol Pathol 29 (Suppl): 147–154.

    Article  CAS  Google Scholar 

  • Walthall K, Cappon GD, Hurtt ME, Zoetis T . (2005). Postnatal development of the gastrointestinal system: A species comparison. Birth Defects Res B Dev Reprod Toxicol 74: 132–156.

    Article  CAS  Google Scholar 

  • Wang SP, Chen XP, Qiu FZ . (2004). A candidate tumor suppressor gene mutated in primary hepatocellular carcinoma: Kruppel-like factor 6. Zhonghua Wai Ke Za Zhi 42: 1258–1261.

    PubMed  Google Scholar 

  • Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, Koritschoner NP et al. (2003). Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 278: 14812–14819.

    Article  CAS  Google Scholar 

  • Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T . (1996). Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev 10: 245–260.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Grant support: SLF: NIH DK37340, the Bendheim Foundation and the Department of Defense, DAMD17-03-1-0100. Xiao Zhao and Goutham Narla were each supported by a Howard Hughes Medical Institute Medical Student Research Fellowship.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S L Friedman.

Additional information

Competing interests statements

The authors disclose that they have no competing financial interests.

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Narla, G., Kremer-Tal, S., Matsumoto, N. et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 26, 4428–4434 (2007). https://doi.org/10.1038/sj.onc.1210223

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210223

Keywords

This article is cited by

Search

Quick links